Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...
Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...
Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...
After a brave battle with Acute Myeloid Leukemia, Polly passed peacefully at the age of 87 surrounded by her loving ...
In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...
Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...
Cops for Kids with Cancer seeks to remove the financial burden for families impacted by a cancer diagnosis. This week they ...
POTOSI – Kathy Ann (Wright) Conway, of Potosi, passed away on February 8, 2025, at Barnes Jewish Hospital in St. Louis, ...
NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies, reported ...
Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback